• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Drug Release Studies Proposed for Combination Products

Drug Release Studies Proposed for Combination Products

Tuesday, 28 September 2021 / Published in Medical Device, News, NMPA Registration in China

Drug Release Studies Proposed for Combination Products

On September 16, 2021, the CMDE (Center for Medical Device Evaluation) of the NMPA released the draft of Technical Review Guidelines for Qualitative, Quantitative and In Vitro Drug Release Studies on Medical Device-based Combination Products. However, the draft guidelines do not cover the scope of drug-based combination products.

Highlights

According to the draft guidelines, drug release studies will be required for medical device-based combination products that intend to release the drug components to certain parts of the body such as drug-eluting stents, drug coated balloon catheters, silver dressings, etc. On the other hand, some products with a different intention such as the artificial blood vessels with covalent boding of heparin will not require drug release studies, but can instead carry out in vitro release studies to assess the stability of the product, the firmness of the coating, etc.

The purpose of the qualitative studies is to confirm the test subject to be studied, and ensure that it does not belong to other kinds of irrelevant substance whilst the purpose of quantitative studies is to accurately determine the amount of drug contained in the combination product. The technical specifications for the drug release studies were further addressed in draft guidelines.

The CMDE is solicitating comments from all experts and personnel related to this industry and the public consultation ends on October 15, 2021.

By Dora Yang and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Combination Products, Drug release studies

What you can read next

Acceptance and Examination of Chemical APIs
Procedures for initiating verification and testing of drug registration (Trial) in 2022
Registration of Infant Formula in China
China water efficiency label
China Water Efficiency Label update in force on July 1, 2022

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.